Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.

MLA

Yokota, Chisato, et al. “Distinct Difference in Tumor-Infiltrating Immune Cells between Wilms’ Tumor Gene 1 Peptide Vaccine and Anti-Programmed Cell Death-1 Antibody Therapies.” Neuro-Oncology Advances, vol. 3, no. 1, June 2021, p. vdab091. EBSCOhost, https://doi.org/10.1093/noajnl/vdab091.

APA

Yokota, C., Nakata, J., Takano, K., Nakajima, H., Hayashibara, H., Minagawa, H., Chiba, Y., Hirayama, R., Kijima, N., Kinoshita, M., Hashii, Y., Tsuboi, A., Oka, Y., Oji, Y., Kumanogoh, A., Sugiyama, H., Kagawa, N., & Kishima, H. (2021). Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Neuro-Oncology Advances, 3(1), vdab091. https://doi.org/10.1093/noajnl/vdab091

Chicago

Yokota, Chisato, Jun Nakata, Koji Takano, Hiroko Nakajima, Hiromu Hayashibara, Hikaru Minagawa, Yasuyoshi Chiba, et al. 2021. “Distinct Difference in Tumor-Infiltrating Immune Cells between Wilms’ Tumor Gene 1 Peptide Vaccine and Anti-Programmed Cell Death-1 Antibody Therapies.” Neuro-Oncology Advances 3 (1): vdab091. doi:10.1093/noajnl/vdab091.